Synaptic basal lamina-associated congenital myasthenic syndromes

Annals of the New York Academy of Sciences

Volumn 1275, Issue 1, 2012, Pages 36-48

  Maselli, Ricardo A ^a   Arredondo, Juan ^a   Ferns, Michael J ^b   Wollmann, Robert L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Agrin; Basal lamina; ColQ; Congenital myasthenic syndromes

Indexed keywords

ACETYLCHOLINESTERASE; AGRIN; CHOLINE ACETYLTRANSFERASE; COLLAGEN TYPE 4; COLLAGEN TYPE 8; ENTACTIN; FIBRONECTIN; FIBULIN; LAMININ; PERLECAN; TENASCIN;

ALPHA HELIX; ARTICLE; BASEMENT MEMBRANE; CARBOXY TERMINAL SEQUENCE; CONGENITAL MYASTHENIC SYNDROME; EATON LAMBERT SYNDROME; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; MUSCLE ACTION POTENTIAL; NEUROMUSCULAR SYNAPSE; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; POSTSYNAPTIC MEMBRANE; PROTEIN ASSEMBLY; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SCHWANN CELL; SCHWARTZ JAMPEL SYNDROME; STEM CELL GENE THERAPY; SYNAPSE VESICLE; SYNAPTIC MEMBRANE;

EID: 84871562988     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06807.x     Document Type: Article

References (92)

1. Colognato, H. & P.D. Yurchenco. 2000. Form and function: the laminin family of heterotrimers. Dev. Dyn. Jun. 218: 213-234.
2. Sanes, J.R. 2003. The basement membrane/basal lamina of skeletal muscle. J. Biol. Chem. 278: 12601-12604.
3. Campbell, K.P. & J.T. Stull. 2003. Skeletal muscle basement membrane-sarcolemma-cytoskeleton interaction minireview series. Biol. Chem. 278: 12599-12600.
4. Yurchenco P.D. & B.L. Patton. 2009. Developmental and pathogenic mechanisms of basement membrane assembly. Curr. Pharm. Des. 15: 1277-1294.
5. Sanes, J.R. et al. 1990. Molecular heterogeneity of basal laminae: isoforms of laminin and collagen IV at the neuromuscular junction and elsewhere. J. Cell Biol. 111: 1685-1699.
6. Miner, J.H. & J.R. Sanes. 1994. Collagen IV alpha 3, alpha 4, and alpha 5 chains in rodent basal laminae: sequence, distribution, association with laminins, and developmental switches. J. Cell Biol. 127: 879-891.
7. Fox, M.A. et al. 2007. Distinct target-derived signals organize formation, maturation, and maintenance of motor nerve terminals. Cell 129: 179-193.
8. Hägg, P. et al. 1998. Type XIII collagen is identified as a plasma membrane protein. J. Biol. Chem. 273: 15590-15597.
9. Peltonen, S. et al. 1999. A novel component of epidermal cell-matrix and cell-cell contacts: transmembrane protein type XIII collagen. J. Invest. Dermatol. 113: 635-642.
10. Snellman, A. et al. 2000. Type XIII collagen forms homotrimers with three triple helical collagenous domains and its association into disulfide-bonded trimers is enhanced by prolyl 4-hydroxylase. J. Biol. Chem. 275: 8936-8944.
11. Massoulié, J. et al. 1998. Acetylcholinesterase: C-terminal domains, molecular forms and functional localization. J. Physiol. Paris 92: 183-190.
12. Rotundo, R.L. 2008. Assembly and regulation of acetylcholinesterase at the vertebrate neuromuscular junction. Chem. Biol. Interact. 175: 26-29.
13. Patton, B.L. et al. 1997. Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J. Cell Biol. 139: 1507-1521.
14. Miner, J.H. et al. 2006. Transgenic isolation of skeletal muscle and kidney defects in laminin beta2 mutant mice: implications for Pierson syndrome. Development 133: 967-975.
15. Fox, M.A. et al. 2008. A synaptic nidogen: developmental regulation and role of nidogen-2 at the neuromuscular junction. Neural. Dev. 25: 3-24.
16. Singhal, N. & P.T. Marin. 2011. Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. Dev. Neurobiol. 71: 982-1005.
17. Ackley, B.D. et al. 2003. The basement membrane components nidogen and type XVIII collagen regulate organization of neuromuscular junctions in Caenorhabditis elegans. J. Neurosci. 23: 3577-3587.
18. Werle, M.J. 2009. Developmental Neurobiology. Academic Press. London.
19. Nishimune, H., J.R. Sanes & S.S. Carlson. 2004. A synaptic laminin-calcium channel interaction organizes active zones in motor nerve terminals. Nature 432: 580-587.
20. Nishimune, H. 2012. Molecular mechanism of active zone organization at vertebrate neuromuscular junctions. Mol. Neurobiol. 45: 1-16.
21. Munoz, J., Y. Zhou & H.W. Jarrett. 2010. LG4-5 domains of laminin-211 binds alpha-dystroglycan to allow myotube attachment and prevent anoikis. J. Cell Physiol. 222: 111-119.
22. Suzuki, N. et al. 2010. Identification of alpha-dystroglycan binding sequences in the laminin alpha2 chain LG4-5 module. Matrix Biol. 29: 143-151.
23. Hohenester, E. et al. 1999. The crystal structure of a laminin G-like module reveals the molecular basis of alpha-dystroglycan binding to laminins, perlecan, and agrin. Mol. Cell. 4: 783-792.
24. Kim, N. et al. 2008. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135: 334-342.
25. Zhang, B. et al. 2008. LRP4 serves as a coreceptor of agrin. Neuron 60: 285-297.
26. Rotundo, R.L. et al. 2008. Assembly and regulation of acetylcholinesterase at the vertebrate neuromuscular junction. Chem. Biol. Interact. 175: 26-29.
27. Cartaud, A. et al., 2004. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J. Cell. Biol. 165: 505-515.
28. LeBleu, V.S., B. Macdonald & R. Kalluri. 2007. Structure and function of basement membranes. Exp. Biol. Med. 232: 1121-1129.
29. Kashtan, C.E. 2009. Familial hematuria. Pediatr. Nephrol. 24: 1951-1958.
30. Miner, J.H. 2011. Organogenesis of the kidney glomerulus: focus on the glomerular basement membrane. Organogenesis 7: 75-82.
31. Rheault, M.N. et al. 2012. Women and Alport syndrome. Pediatr. Nephrol. 27: 41-46.
32. Zenker, M. et al. 2004. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum. Mol. Genet. 13: 2625-2632.
33. Zenker, M. et al. 2004. Congenital nephrosis, mesangial sclerosis, and distinct eye abnormalities with microcoria: an autosomal recessive syndrome. Am. J. Med. Genet. A. 130: 138-145.
34. Maselli, R.A. et al. 2009. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J. Med. Genet. 46: 203-208.
35. Matejas, V. et al. 2010. Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum. Mutat. 31: 992-1002.
36. Nicole, S. et al. 2000. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat. Genet. 26: 480-483.
37. Arikawa-Hirasawa, E. et al. 2002. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am. J. Hum. Genet. 70: 1368-1375.
38. Bangratz, M. et al. 2012. A mouse model of Schwartz-Jampel syndrome reveals myelinating Schwann cell dysfunction with persistent axonal depolarization in vitro and distal peripheral nerve hyperexcitability when perlecan is lacking. Am. J. Pathol. 180: 2040-2055.
39. Knöll, R. et al. 2007. Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 116: 515-525.
40. Wang, J. et al. 2006. Cardiomyopathy associated with microcirculation dysfunction in laminin alpha4 chain-deficient mice. J. Biol. Chem. 281: 213-220.
41. Abrass, C.K., K.M. Hansen & B.L. Patton. 2010. Laminin alpha4-null mutant mice develop chronic kidney disease with persistent overexpression of platelet-derived growth factor. Am. J. Pathol. 176: 839-849.
42. Nishimune H et al. 2008. Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction. J. Cell Biol. 182: 1201-1215.
43. Patton, B.L. et al. 2001. Properly formed but improperly localized synaptic specializations in the absence of laminin alpha4. Nat. Neurosci. 4: 597-604.
44. Xu, H. et al. 1994. Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat. Genet. 8: 297-302.
45. Helbling-Leclerc, A. et al. 1995. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat. Genet. 11: 216-218.
46. Naom, I.S. et al. 1997. Refinement of the laminin alpha2 chain locus to human chromosome 6q2 in severe and mild merosin deficient congenital muscular dystrophy. J. Med. Genet. 34: 99-104.
47. Patton, B.L. 2000. Laminins of the neuromuscular system. Microsc. Res. Tech. 51: 247-261.
48. Miner, J.H., J. Cunningham & J.R. Sanes. 1998. Roles for laminin in embryogenesis: exencephaly, syndactyly, and placentopathy in mice lacking the laminin α5 chain. J. Cell Biol. 143: 1713-1723.
49. Smyth, N. et al. 1999. Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endodermdifferentiation. J. Cell Biol. 144: 151-160.
50. Latvanlehto A. et al. 2010. Muscle-derived collagen XIII regulates maturation of the skeletal neuromuscular junction. J. Neurosci. 30: 12230-12241.
51. Heidet, L. et al. 1995. Deletions of both alpha 5(IV) and alpha 6(IV) collagen genes in Alport syndrome and in Alport syndrome associated with smooth muscle tumours. Hum. Mol. Genet. 4: 99-108.
52. Dong, L. et al. 2002. Neurologic defects and selective disruption of basement membranes in mice lacking entactin-1/nidogen-1. Lab. Invest. 82: 1617-1630.
53. Shannon, M.B. et al. 2006. Hypomorphic mutation in the mouse laminin α5 gene (Lama5) causes polycystic kidney disease. J. Am. Soc. Nephrol. 17: 1913-1922.
54. Engel, A.G., E.H. Lambert & M.R. Gomez. 1977. New myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann. Neurol. 1: 315-330.
55. Huzé, C. et al. 2009. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am. J. Hum. Genet. 85: 155-167.
56. Gautam, M. et al. 1996. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85: 525-535.
57. Noakes, P.G. et al. 1995. Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin/laminin beta 2. Nature 374: 258-262.
58. Feng, G. et al. 1999. Genetic analysis of collagen Q: roles in acetylcholinesterase and butyrylcholinesterase assembly and in synaptic structure and function. J. Cell Biol. 144: 1349-1360.
59. Maselli, R.A. et al. 2012. LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin. Hum. Genet. 131: 1123-1135.
60. Engel, A.G. 2012. Current status of the congenital myasthenic syndromes. Neuromusc. Disord. 22: 99-111.
61. Feng, G. et al. 1999. Genetic analysis of collagen Q: roles in acetylcholinesterase and butyrylcholinesterase assembly and in synaptic structure and function. J. Cell Biol. 144: 1349-1360.
62. Laskowski, M.B., W.H. Olson & W.D. Dettbarn. 1975. Ultrastructural changes at the motor end-plate produced by an irreversible cholinesterase inhibitor. Exp. Neurol. 47: 290-306.
63. Salpeter, M.M. et al. 1979. End-plates after esterase inactivation in vivo: correlation between esterase concentration, functional response and fine structure. J. Neurocytol. 8: 95-115.
64. Engel, A.G. et al. 1982. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann. Neurol. 11: 553-569.
65. Vohra, B.P. et al. 2004. Focal caspase activation underlies the endplate myopathy in slow-channel syndrome. Ann. Neurol. 55: 347-352.
66. Engel, A.G. et al. 1996. End-plate acetylcholine receptor deficiency due to nonsense mutations in the epsilon subunit. Ann. Neurol. 40: 810-817.
67. Ohno, K. et al. 2002. Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am. J. Hum. Genet. 70: 875-885.
68. Anderson, J.A. et al. 2008. Variable phenotypes associated with mutations in DOK7. Muscle Nerve 37: 448-456.
69. Maselli, R.A. et al. 2010. Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction. Hum. Mol. Genet. 19: 2370-2379.
70. Maselli, R.A. & B.C. Soliven. 1991. Analysis of the organophosphate-induced electromyographic response to repetitive nerve stimulation: paradoxical response to edrophonium and D-tubocurarine. Muscle Nerve 14: 1182-1188.
71. Maselli, R., J.H. Jacobsen & J.P. Spire. 1986. Edrophonium: an aid in the diagnosis of acute organophosphate poisoning. Ann. Neurol. 19: 508-510.
72. Maselli, R.A. & C. Leung. 1993. Analysis of anticholinesterase-induced neuromuscular transmission failure. Muscle Nerve 16: 548-553.
73. Ohno, K. et al. 1998. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc. Natl. Acad. Sci. USA 95: 9654-9659.
74. Chaouch, A. et al. 2012. 186th ENMC international workshop: congenital myasthenic syndromes 24-26 June 2011, Naarden, The Netherlands. Neuromuscul. Disord. 22: 566-576.
75. Massoulié, J. 2002. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 11: 130-143.
76. Massoulié, J. & C.B. Millard. 2009. Cholinesterases and the basal lamina at vertebrate neuromuscular junctions. Curr. Opin. Pharmacol. 9: 316-325.
77. Ellman, G.L. et al. 1961. Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol 7: 88-95.
78. Hall, Z.W. 1973. Multiple forms of acetylcholinesterase and their distribution in endplate and non-endplate regions of rat diaphragm muscle. J. Neurobiol. 4: 343-361.
79. Ohno, K. et al. 2000. The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Ann. Neurol. 47: 162-170.
80. Donger, C. et al. 1998. Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic). Am. J. Hum. Genet. 63: 967-975.
81. Maselli, R. et al. 2003. Endplate (EP) acetylcholinesterase (AChE) deficiency due to COLQ mutations: missense mutations in the C-terminal do not prevent assembly of COLQ to the catalytic subunit. Neurology 60(Suppl): A389.
82. Kimbell, L.M. et al. 2004. C-terminal and heparin-binding domains of collagenic tail subunit are both essential for anchoring acetylcholinesterase at the synapse. J. Biol. Chem. 279: 10997-11005.
83. Arredondo et al. COOH-terminal COLQ mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with protein of the basal lamina. In preparation.
84. Ohno, K. et al. 2001. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc. Natl. Acad. Sci. USA 98: 2017-2022.
85. Mihaylova, V. et al. 2008. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 131: 747-759.
86. Bestue-Cardiel, M. et al. 2005. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65: 144-146.
87. Liewluck, T., D. Selcen & A.G. Engel. 2011. Beneficial effects of Albuterol in congenital endplate acetylcholinesterase deficiency and DOK-7 myasthenia. Muscle Nerve 44: 789-794.
88. Guven, A., M. Demirci & B. Anlar. 2012. Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatr. Neurol. 46: 253-256.
89. Ito, M. et al. 2012. Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction. Mol. Ther. 20: 1384-1392.
90. Belaya, K., S. Finlayson, J. Cossins, W.W. Liu, S. Maxwell, J. Palace & D. Beeson. 2012. Identification of DPAGT1 as a new gene in which mutations cause a congenital myasthenic syndrome. Ann. N.Y. Acad. Sci. 1275: 29-35.
91. Knight, D. et al. 2003. Functional analysis of neurotransmission at β2-laminin deficient terminals. J. Physiol. 546: 789-800.
92. Patton, B.L., A.Y. Chiu & J.R. Sanes. 1998. Synaptic laminin prevents glial entry into the synaptic cleft. Nature 393: 698-701.